Last reviewed · How we verify
Placebo to match ruxolitinib
Placebo to match ruxolitinib is a Small molecule drug developed by Sierra Oncology LLC - a GSK company. It is currently in Phase 3 development for Myelofibrosis.
This drug is a placebo used to match the effects of ruxolitinib.
This drug is a placebo used to match the effects of ruxolitinib. Used for Myelofibrosis.
At a glance
| Generic name | Placebo to match ruxolitinib |
|---|---|
| Sponsor | Sierra Oncology LLC - a GSK company |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not have a specific mechanism of action, but rather serves as a control group in clinical trials to compare the efficacy of ruxolitinib.
Approved indications
- Myelofibrosis
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) (PHASE3)
- A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis (PHASE3)
- Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (PHASE3)
- Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis (PHASE3)
- A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA) (PHASE2)
- A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) (PHASE3)
- Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (PHASE3)
- Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match ruxolitinib CI brief — competitive landscape report
- Placebo to match ruxolitinib updates RSS · CI watch RSS
- Sierra Oncology LLC - a GSK company portfolio CI
Frequently asked questions about Placebo to match ruxolitinib
What is Placebo to match ruxolitinib?
How does Placebo to match ruxolitinib work?
What is Placebo to match ruxolitinib used for?
Who makes Placebo to match ruxolitinib?
What development phase is Placebo to match ruxolitinib in?
What are the side effects of Placebo to match ruxolitinib?
Related
- Manufacturer: Sierra Oncology LLC - a GSK company — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Myelofibrosis